Is This the Right Time to Hold Thermo Fisher Stock in Your Portfolio?

Key Takeaways Thermo Fisher is expanding via deals, including Clario for $8.875B and Solventum's filtration unit. TMO posted high single-digit Q4 Pharma & Biotech growth, led by bioproduction and research demand. TMO faces FX risks as global sales grow, while competition and tech shifts pressure operations.Thermo Fisher Scientific Inc.’s (TMO) recent slew of strategic acquisitions reflects its ongoing commitment to sustainable long-term growth. End markets play an important role as well, bolstering the comp ...